S&P 500   3,761.31 (-2.29%)
DOW   30,426.36 (-1.65%)
QQQ   320.35 (-2.51%)
AAPL   142.17 (-0.69%)
MSFT   231.93 (-0.17%)
FB   271.35 (-3.79%)
GOOGL   1,817.19 (-4.76%)
AMZN   3,247.57 (-2.36%)
TSLA   870.37 (-1.44%)
NVDA   517.66 (-3.68%)
BABA   261.81 (-1.55%)
CGC   37.77 (+6.33%)
GE   10.82 (-4.16%)
MU   75.17 (-5.46%)
AMD   89.11 (-5.91%)
NIO   57.06 (-5.39%)
T   29.12 (-2.12%)
F   10.77 (-3.75%)
ACB   11.35 (+6.37%)
BA   192.96 (-4.50%)
DIS   162.60 (-4.10%)
NFLX   533.01 (-5.15%)
GILD   65.57 (-1.69%)
S&P 500   3,761.31 (-2.29%)
DOW   30,426.36 (-1.65%)
QQQ   320.35 (-2.51%)
AAPL   142.17 (-0.69%)
MSFT   231.93 (-0.17%)
FB   271.35 (-3.79%)
GOOGL   1,817.19 (-4.76%)
AMZN   3,247.57 (-2.36%)
TSLA   870.37 (-1.44%)
NVDA   517.66 (-3.68%)
BABA   261.81 (-1.55%)
CGC   37.77 (+6.33%)
GE   10.82 (-4.16%)
MU   75.17 (-5.46%)
AMD   89.11 (-5.91%)
NIO   57.06 (-5.39%)
T   29.12 (-2.12%)
F   10.77 (-3.75%)
ACB   11.35 (+6.37%)
BA   192.96 (-4.50%)
DIS   162.60 (-4.10%)
NFLX   533.01 (-5.15%)
GILD   65.57 (-1.69%)
S&P 500   3,761.31 (-2.29%)
DOW   30,426.36 (-1.65%)
QQQ   320.35 (-2.51%)
AAPL   142.17 (-0.69%)
MSFT   231.93 (-0.17%)
FB   271.35 (-3.79%)
GOOGL   1,817.19 (-4.76%)
AMZN   3,247.57 (-2.36%)
TSLA   870.37 (-1.44%)
NVDA   517.66 (-3.68%)
BABA   261.81 (-1.55%)
CGC   37.77 (+6.33%)
GE   10.82 (-4.16%)
MU   75.17 (-5.46%)
AMD   89.11 (-5.91%)
NIO   57.06 (-5.39%)
T   29.12 (-2.12%)
F   10.77 (-3.75%)
ACB   11.35 (+6.37%)
BA   192.96 (-4.50%)
DIS   162.60 (-4.10%)
NFLX   533.01 (-5.15%)
GILD   65.57 (-1.69%)
S&P 500   3,761.31 (-2.29%)
DOW   30,426.36 (-1.65%)
QQQ   320.35 (-2.51%)
AAPL   142.17 (-0.69%)
MSFT   231.93 (-0.17%)
FB   271.35 (-3.79%)
GOOGL   1,817.19 (-4.76%)
AMZN   3,247.57 (-2.36%)
TSLA   870.37 (-1.44%)
NVDA   517.66 (-3.68%)
BABA   261.81 (-1.55%)
CGC   37.77 (+6.33%)
GE   10.82 (-4.16%)
MU   75.17 (-5.46%)
AMD   89.11 (-5.91%)
NIO   57.06 (-5.39%)
T   29.12 (-2.12%)
F   10.77 (-3.75%)
ACB   11.35 (+6.37%)
BA   192.96 (-4.50%)
DIS   162.60 (-4.10%)
NFLX   533.01 (-5.15%)
GILD   65.57 (-1.69%)
Log in
TSE:APS

Aptose Biosciences Stock Forecast, Price & News

C$5.43
-0.02 (-0.37 %)
(As of 01/27/2021 02:58 PM ET)
Add
Compare
Today's Range
C$5.25
Now: C$5.43
C$5.69
50-Day Range
C$5.15
MA: C$5.55
C$6.48
52-Week Range
C$5.00
Now: C$5.43
C$12.62
Volume48,808 shs
Average Volume39,970 shs
Market CapitalizationC$482.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

MarketRank

Overall MarketRank

1.26 out of 5 stars

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-647-4799828
Employees31
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$1.45 per share
Book ValueC$1.45 per share

Profitability

Miscellaneous

Market CapC$482.52 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
C$5.43
-0.02 (-0.37 %)
(As of 01/27/2021 02:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APS News and Ratings via Email

Sign-up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aptose Biosciences (TSE:APS) Frequently Asked Questions

How has Aptose Biosciences' stock price been impacted by Coronavirus (COVID-19)?

Aptose Biosciences' stock was trading at C$7.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, APS stock has decreased by 31.5% and is now trading at C$5.43.
View which stocks have been most impacted by COVID-19
.

Is Aptose Biosciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptose Biosciences stock.
View analyst ratings for Aptose Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aptose Biosciences?

Wall Street analysts have given Aptose Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptose Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Aptose Biosciences
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (TSE:APS) posted its quarterly earnings data on Tuesday, November, 10th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.04.
View Aptose Biosciences' earnings history
.

What price target have analysts set for APS?

2 brokerages have issued 12-month target prices for Aptose Biosciences' shares. Their forecasts range from C$12.00 to C$12.00. On average, they expect Aptose Biosciences' stock price to reach C$12.00 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price.
View analysts' price targets for Aptose Biosciences
or view Wall Street analyst' top-rated stocks.

Who are some of Aptose Biosciences' key competitors?

What other stocks do shareholders of Aptose Biosciences own?

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the following people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS."

How do I buy shares of Aptose Biosciences?

Shares of APS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What is Aptose Biosciences' stock price today?

One share of APS stock can currently be purchased for approximately C$5.43.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of C$482.52 million. Aptose Biosciences employs 31 workers across the globe.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is aptose.com.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The biotechnology company can be reached via phone at +1-647-4799828.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.